National Institute on Drug Abuse; Notice of Closed Meeting, 81832 [2015-32937]

Download as PDF 81832 Federal Register / Vol. 80, No. 251 / Thursday, December 31, 2015 / Notices TABLE A.12–1.3—ESTIMATE OF RESPONDENT BURDEN, GENERATION 3 COHORT, NOS AND OMNI GROUP 2 COHORT— Continued [Annualized] Number of respondents Type of respondent Number of responses per respondent Average time per response (hours per year) Total annual burden hour 2. Home or nursing home visit ................................................................. C. POST-EXAM: eFHS Mobile Technology for Collection of CVD Risks ............................ D. ANNUAL FOLLOW-UP: 1. Records Request .................................................................................. 2. Health Status Update ........................................................................... 35 1 60/60 35 1,100 18 9/60 2,970 1,200 1,400 1 1 15/60 15/60 300 350 Sub-Total: Participant Components .................................................. * 2,850 ........................ ........................ 6,830 II. NON-PARTICIPANT COMPONENTS—ANNUAL FOLLOW-UP A. INFORMANT CONTACTS .......................................................................... B. RECORD REQUEST .................................................................................. 180 1,155 1 1 10/60 15/60 30 289 Sub-Total: Non-Participant Components .................................................. 1,335 ........................ ........................ 319 Total: Participant And Non-Participant Components ........................ 4,185 ........................ ........................ 7,157 * Number of participants as reflected in Rows I.A.1 and I.D.2 above. Dated: December 22, 2015. Valery Gheen, NHLBI Project Clearance Liaison, National Institutes of Health. Place: Intramural Research Program, National Institute on Drug Abuse, NIH, Johns Hopkins Bayview Campus, Baltimore, MD 21223. Contact Person: Joshua Kysiak, Program Specialist, Biomedical Research Center, Intramural Research Program, National Institute on Drug Abuse, NIH, DHHS, 251 Bayview Boulevard, Baltimore, MD 21224, 443–740–2465, kysiakjo@nida.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS) [FR Doc. 2015–32940 Filed 12–30–15; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health tkelley on DSK3SPTVN1PROD with NOTICES National Institute on Drug Abuse; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App.), notice is hereby given of a meeting of the Board of Scientific Counselors, NIDA. The meeting will be closed to the public as indicated below in accordance with the provisions set forth in section 552b(c)(6), Title 5 U.S.C., as amended for the review, discussion, and evaluation of individual intramural programs and projects conducted by the National Institute on Drug Abuse, including consideration of personnel qualifications and performance, and the competence of individual investigators, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: Board of Scientific Counselors, NIDA. Date: February 1–2, 2016. Closed: 8:30 a.m. to 5:00 p.m. Agenda: To review and evaluate personal qualifications and performance, and competence of individual investigators. VerDate Sep<11>2014 16:49 Dec 30, 2015 Jkt 238001 Dated: December 28, 2015. Natasha M. Copeland, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2015–32939 Filed 12–30–15; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute on Drug Abuse; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. App), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable materials, and personal information concerning PO 00000 Frm 00028 Fmt 4703 Sfmt 4703 individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute on Drug Abuse Special Emphasis Panel; Tools for Monitoring and Manipulating RNA Modifications (R41, R42, R43, R44). Date: February 18, 2016. Time: 9:00 a.m. to 4:00 p.m. Agenda: To review and evaluate grant applications. Place: Hilton Garden Inn Bethesda, 7301 Waverly Street, Bethesda, MD 20814. Contact Person: Jagadeesh S. Rao, Ph.D., Scientific Review Officer, Office of Extramural Policy and Review, National Institute on Drug Abuse, National Institutes of Health, DHHS, 6001 Executive Boulevard, Room 4234, MSC 9550, Bethesda, MD 02892, 301–443–9511, jrao@nida.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug Abuse and Addiction Research Programs, National Institutes of Health, HHS) Dated: December 28, 2015. Natasha M. Copeland, Program Analyst, Office of Federal Advisory Committee Policy. [FR Doc. 2015–32937 Filed 12–30–15; 8:45 am] BILLING CODE 4140–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Allergy and Infectious Diseases; Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as E:\FR\FM\31DEN1.SGM 31DEN1

Agencies

[Federal Register Volume 80, Number 251 (Thursday, December 31, 2015)]
[Notices]
[Page 81832]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-32937]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute on Drug Abuse; Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App), notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable materials, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute on Drug Abuse Special 
Emphasis Panel; Tools for Monitoring and Manipulating RNA 
Modifications (R41, R42, R43, R44).
    Date: February 18, 2016.
    Time: 9:00 a.m. to 4:00 p.m.
    Agenda: To review and evaluate grant applications.
    Place: Hilton Garden Inn Bethesda, 7301 Waverly Street, 
Bethesda, MD 20814.
    Contact Person: Jagadeesh S. Rao, Ph.D., Scientific Review 
Officer, Office of Extramural Policy and Review, National Institute 
on Drug Abuse, National Institutes of Health, DHHS, 6001 Executive 
Boulevard, Room 4234, MSC 9550, Bethesda, MD 02892, 301-443-9511, 
jrao@nida.nih.gov.

(Catalogue of Federal Domestic Assistance Program Nos.: 93.279, Drug 
Abuse and Addiction Research Programs, National Institutes of 
Health, HHS)

    Dated: December 28, 2015.
Natasha M. Copeland,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2015-32937 Filed 12-30-15; 8:45 am]
BILLING CODE 4140-01-P
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.